-
Product Insights
NewLikelihood of Approval Analysis for Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD))
Overview How likely is it that the drugs in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Overview Adrenoleukodystrophy is a disorder that...
-
Product Insights
NewLikelihood of Approval Analysis for X Chromosome Disorders
Overview How likely is it that the drugs in X Chromosome Disorders will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. X Chromosome Disorders Overview X chromosome disorders, also termed X-linked disorders,...
-
Product Insights
NewLikelihood of Approval Analysis for Recessive X Chromosome Disorders
Overview How likely is it that the drugs in Recessive X Chromosome Disorders will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Recessive X Chromosome Disorders Overview A recessive X chromosome disorder,...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NA-921 in Fragile X Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NA-921 in Fragile X Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NA-921 in Fragile X Syndrome Drug Details: NA-921 is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – MB-207 in X-Linked SCID
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - MB-207 in X-Linked SCID report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. MB-207 in X-Linked SCID Drug Details: MB-207 is under development for the...
-
Product Insights
NewFragile X Syndrome Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Fragile X Syndrome Clinical Trial Report Overview A total of 110 fragile X syndrome clinical trials were conducted as of March 2024. The fragile X syndrome clinical trial report provides a comprehensive understanding of the fragile X syndrome clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Leriglitazone Hydrochloride in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD))
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Leriglitazone Hydrochloride in Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) Drug Details: Leriglitazone hydrochloride is under development for...
-
Product Insights
Fragile X Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Fragile X Syndrome - Drugs In Development, 2023’, provides an overview of the Fragile X Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Fragile X Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Coagulation Factor X – Drugs In Development, 2023
Global Markets Direct’s Coagulation Factor X provides in depth analysis on Coagulation Factor X targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Coagulation Factor X targeted therapeutics...